Sermorelin 5mg Dosage Protocol

Educational guide for reconstitution and administration of Sermorelin, a growth hormone releasing hormone analog.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Subcutaneous Protocol (3 mL = 1.67 mg/mL)

Frequency: Inject once or twice daily subcutaneously. Due to the compound's plasma half-life of approximately 3.8–6.9 hours, twice-daily (BID) dosing may provide more sustained NNMT inhibition. Note: A single 10 mg vial provides only 2–4 days of research material at these doses.

Reconstitution Steps

1. Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
2. Draw 2.0 mL bacteriostatic water with a sterile syringe.
3. Inject slowly down the vial wall; avoid foaming.
4. Gently swirl/roll until dissolved—solution should be clear (do not shake).
5. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.

Biological Action

Sermorelin represents a synthetic analog of growth hormone releasing hormone (GHRH), specifically the C-terminal end of the naturally occurring GHRH molecule.

As a GHRH analog, Sermorelin binds to pituitary GHRH receptors to stimulate the pulsatile release of growth hormone from the anterior pituitary gland.

Sermorelin has been studied extensively for its role in supporting natural growth hormone production and metabolic regulation in research contexts.

Potential Benefits & Side Effects

Findings from endocrinology and growth hormone research.

• Potential to support natural growth hormone production in research settings
• May assist with metabolic regulation and body composition studies
• Associated with GHRH receptor activation and hormonal balance
• Generally well tolerated; occasional mild injection reactions
• Human safety profile remains under investigation; not approved for therapeutic use
• Long-term human safety data not established; this compound remains investigational

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
5. Slow injection may minimize any stinging sensation associated with the compound.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each administration; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; a mild stinging sensation may occur due to the quinolinium structure.
• Document daily dose and site rotation to maintain consistency.
• The 10 mg vial format is suited for short-term tolerance assessment; extended protocols require multiple vials.

References